Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry
Authors' conclusion
We found comparable survival in rheumatoid arthritis and ankylosing spondylitis. In psoriatic arthritis, we found significantly shorter survival on etanercept, possibly due to worse response of skin and nail manifestations.
Study context
- Population
- Patients with RA, AS or PsA initiating first line biological therapy with TNF-α inhibitors, Czech ATTRA registrymatched within each disease
- Exposure
- Etanercept vs monoclonal antibody TNF-α inhibitors as first-line biological therapy
- Outcome
- Drug survival
Methodological detailspropensity-score matched, registry-based (Czech ATTRA registry), Kaplan-Meier analysis
- Propensity-score matched
- Registry-based (Czech ATTRA registry)
- Kaplan-Meier analysis
Main finding
As reported in the abstract
Drug survival (median survival time on drug), by disease
HR for drug discontinuation
0.94
P = 0.416
RA; 657 matched to 657
HR for drug discontinuation
0.78
P = 0.087
AS; 187 matched to 356
HR for drug discontinuation
1.61
P = 0.011
PsA; 81 matched to 160
Observational data: associations, not effects.
Further findings
Psoriasis scoring during follow-up
- Significantly worse psoriasis scoring with etanercept
Original publication
Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry. Scand J Rheumatol. Published 6 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →